fibrosis, cardiac fibrosis, organ transplant, vascular stenosis, restenosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, pleural fibrosis and COPD, a disease in which airway walls are fibrotic with the accumulation of myofibroblasts and collagen, and like all fibrotic tissues, are contracted.

6. Use of a VAP-1 inhibitor according to any of the claims 1-4 for the manufacture of a medicament for the treatment of a fibrotic condition.

7. The use according to claim 86, wherein said fibrotic condition is selected from a group consisting of liver fibrosis and the inflammatory conditions which predispose to it ie acute and chronic hepatitis, biliary disease and toxic liver injury, pulmonary fibrosis, renal fibrosis, including that resulting from diabetic nephropathy, myelofibrosis, pancreatic fibrosis, scleroderma, connective tissue diseases, scarring, skin fibrosis, cardiac fibrosis, organ transplant, vascular stenosis, restenosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, pleural fibrosis and COPD, a disease in which airway walls are fibrotic with the accumulation of myofibroblasts and collagen, and like all fibrotic tissues, are contracted.

~~8. A method of preventing, treating or alleviating a fibrotic condition~~ in a human subject in need thereof, said method comprising administering to said patient an efficient amount of a VAP-1 inhibitor.

9. The method according to claim 8, wherein said VAP-1 inhibitor is selected from a group consisting of anti-VAP-1 antibodies and SSAO inhibitors.

10. The method according to claim 9, wherein said antibody is a fully human anti-VAP-1 antibody comprising one to three CDR consensus sequences selected from a group consisting of SEQ ID NOs 1 to 3 and/or a light chain polypeptide comprising one to three CDR consensus sequences selected from a group consisting of SEQ ID NOs 24 to 26.

11. The method according to claim 9, wherein said antibody has a heavy chain polypeptide comprising a first CDR sequence selected from SEQ ID NOs 4 to 8, a second CDR sequence selected from SEQ ID NOs 9 to 13, and a third CDR sequence selected from SEQ ID NOs 14 to 18, and/or a light chain polypeptide comprising a first CDR sequence selected from SEQ ID NOs 27 to 31, a second CDR sequence selected from SEQ ID NOs 32 to 36 and a ~~third CDR sequence selected from SEQ ID NOs 37 to 41.~~

~~12. The method according to claim 9, wherein said antibody has a~~ heavy chain variable region comprising an amino acid sequence selected from a group consisting of SEQ ID NOs 19 to 23, and a respective light chain variable region comprising an amino acid sequence selected from a group consisting of SEQ ID NOs 42 to 46.

13. The method according to claim 9, wherein said antibody is a fully human recombinant antibody comprising a heavy chain polypeptide depicted in SEQ ID NO 47 and a light chain polypeptide depicted in SEQ ID NO 48.

14. The method according to claim 9, wherein said SSAO inhibitor is selected from a group consisting of hydrazine derivatives, propenyl- and propargylamines, 4-substituted-2-butynylamines, haloallylamines, pyrroline derivatives, propargyldiamines, allylamines, diamines, 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivatives, thiocarbamoyl derivatives, carboxamides, sulfonamides, thiazole and/or guanidine derivatives, oxime derivatives, dihydrazine, arylalkylamines, oxazolidinones, haloalkylamines, benfotiamine, and imidazopyridine derivatives.

15. The method according to claim 8, wherein said fibrotic condition is selected from a group consisting of liver fibrosis and the inflammatory conditions which predispose to acute and chronic hepatitis, biliary disease and toxic liver injury, pulmonary fibrosis, renal fibrosis, including that resulting from diabetic nephropathy, myelofibrosis, pancreatic fibrosis, scleroderma, connective tissue diseases, scarring, skin fibrosis, cardiac fibrosis, organ transplant, vascular stenosis, restenosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, pleural fibrosis and COPD, a disease in which airway walls are fibrotic with the accumulation of myofibroblasts and collagen, and like ~~all fibrotic tissues, are contracted.~~

~~16~~8. A method of diagnosing a fibrotic condition in a subject, said method comprising:

a) providing a sample of a bodily fluid from said subject,

b) assaying the amount of soluble VAP-1 (sVAP-1) or SSAO activity in said sample,

c) diagnosing fibrosis on the basis of said amount of sVAP-1 or SSAO activity.

~~17~~9. The method according to claim ~~16~~ 8, wherein the amount of sVAP-1 or SSAO activity is compared to the amount of sVAP-1 or SSAO activity in a reference bodily fluid.

~~18~~10. The method according to claim ~~16~~ 8, wherein the amount of sVAP-1 is determined using a VAP-1 specific antibody.

~~19~~11. The method according to claim ~~24~~ 8, wherein the bodily fluid is serum or plasma.

~~20~~12. The method according to claim ~~16~~ 8, wherein said fibrotic condition is selected from a group consisting of liver fibrosis and inflammatory conditions which predispose to acute and chronic hepatitis, biliary disease and toxic liver injury, pulmonary fibrosis, renal fibrosis, including that resulting from diabetic nephropathy, myelofibrosis, pancreatic fibrosis, scleroderma, connective tissue diseases, scarring, skin fibrosis, cardiac fibrosis, organ transplant, vascular stenosis, restenosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, pleural fibrosis and COPD, a disease in which airway walls are fibrotic with the accumulation of myofibroblasts and collagen, and like all fibrotic tissues, are contracted.

~~21~~13. The method according to claim ~~16~~ 8, wherein said diagnosing includes determining the degree of fibrosis.

~~22~~14. A kit for use in the method according to claim ~~16~~ 8, comprising one or more reagents for assessing the amount sVAP-1 or SSAO activity in a bodily fluid.

~~23~~15. The kit according to claim ~~30~~ 14 for assessing the amount of sVAP-1, comprising a specific anti-VAP-1 antibody.